AI Analysis | Feedback

Here are 1-3 brief analogies to describe Chemed:

• For its hospice division (VITAS): The HCA Healthcare of end-of-life care.

• For its plumbing division (Roto-Rooter): The McDonald's of plumbing services.

AI Analysis | Feedback

• Hospice Care: Through its Vitas Healthcare segment, Chemed provides hospice and palliative care services to patients facing life-limiting illnesses.
• Plumbing, Drain, and Water Cleanup Services: The Roto-Rooter segment offers a range of services including plumbing repair, drain cleaning, and water damage restoration for residential and commercial customers.

AI Analysis | Feedback

Chemed Corporation (CHE) operates in two main business segments: VITAS Healthcare and Roto-Rooter. Based on these operations, Chemed primarily sells services directly to individuals and businesses, rather than selling to other companies that then resell Chemed's services.

Therefore, its major customers can be described by the following categories:

• Patients with life-limiting illnesses: Through its VITAS Healthcare segment, Chemed provides hospice care services directly to individuals facing end-of-life conditions and their families. Medicare, Medicaid, and private insurance companies are the primary payers for these services, but the direct recipients and beneficiaries of the services are the individual patients.
• Residential homeowners: Through its Roto-Rooter segment, Chemed provides plumbing, drain cleaning, and water cleanup services directly to individual homeowners for their residential properties.
• Commercial businesses: Also through its Roto-Rooter segment, Chemed provides plumbing, drain cleaning, and water cleanup services directly to various commercial enterprises such as restaurants, retail stores, office buildings, and industrial facilities.

AI Analysis | Feedback

AI Analysis | Feedback

Kevin J. McNamara, President and Chief Executive Officer

Mr. McNamara joined Chemed in 1980 as a corporate attorney. In 1981, he moved to Omnicare, Inc., then a 24%-owned affiliate of Chemed, serving as Secretary. He returned to Chemed in 1986, where he was named Vice President, General Counsel, and Secretary. From 1990 to 1992, he also held the positions of Executive Vice President and Chief Operating Officer at Omnicare. He was elected Vice Chairman of Chemed in 1992, and subsequently Executive Vice President, Secretary, and General Counsel in 1993. Mr. McNamara became President in 1994 and assumed the role of Chief Executive Officer in 2001. Since February 2004, he has also served as Chairman of Chemed's VITAS Healthcare Corporation subsidiary.

Michael D. Witzeman, Vice President, Chief Financial Officer, and Controller

Mr. Witzeman has served as the Chief Financial Officer, Vice President, and Controller of Chemed since January 2024. Prior to this role, he was the Vice President and Controller of the company. Before his tenure at Chemed, he worked as a Senior Manager of Assurance at Deloitte & Touche LLP.

Nicholas M. Westfall, Executive Vice President

Mr. Westfall is the Executive Vice President of Chemed Corporation and also serves as the Chief Executive Officer of VITAS Healthcare Corporation. He joined Chemed in 2009 as Director of Information Technology and Operations. In 2012, he moved to VITAS as Senior Vice President of Field Operations, progressing to Chief Operating Officer in 2015. In June 2016, he was elected Executive Vice President of Chemed and simultaneously promoted to Chief Executive Officer of VITAS.

Spencer S. Lee, Executive Vice President

Mr. Lee holds the title of Executive Vice President at Chemed Corporation.

Brian C. Judkins, Vice President, Secretary and Chief Legal Officer

Mr. Judkins was promoted to Secretary and Chief Legal Officer in August 2020. He began his career at Chemed in January 2019 as Vice President and Counsel. Prior to joining Chemed, Mr. Judkins was a partner at Dinsmore & Shohl, LLP, where he specialized in corporate and mergers and acquisitions (M&A) practice.

AI Analysis | Feedback

Chemed Corporation (CHE) faces several key risks to its business, primarily stemming from its two main segments: VITAS Healthcare and Roto-Rooter. The most significant risks include:

1. Regulatory and Reimbursement Risks for VITAS Healthcare: Chemed's VITAS Healthcare subsidiary, which derives over 90% of its revenue from Medicare and Medicaid, is highly susceptible to changes in government regulations and reimbursement policies. Key concerns include periodic changes in reimbursement levels, difficulties in predicting patient length of stay, and estimating Medicare reimbursement obligations. For instance, VITAS has grappled with Medicare Cap limitations, particularly in Florida, which have led to projected revenue shortfalls and threatened near-term profitability. The company also faces ongoing scrutiny regarding compliance with Medicare and Medicaid billing requirements, evidenced by past False Claims Act allegations.
2. Labor Shortages: Both of Chemed's segments are vulnerable to labor shortages. VITAS Healthcare faces a persistent shortage of qualified nurses and other healthcare professionals, which can impact its ability to provide services and manage costs. Similarly, the Roto-Rooter segment experiences a shortage of licensed plumbing and drain cleaning technicians. These shortages can lead to increased labor costs and operational challenges across the company.
3. Operational Challenges and Competitive Pressures in Roto-Rooter: The Roto-Rooter segment has experienced recent revenue declines, particularly in its commercial and residential services, and decreased residential demand. This segment operates in a highly competitive and fragmented market, with competition from numerous local and regional firms. Additionally, Roto-Rooter has faced increased variable expenses, impacting its gross margin. Macroeconomic headwinds, such as inflationary trends, increased logistics costs, and higher employee-related expenses, further contribute to the operational challenges faced by this segment.

AI Analysis | Feedback

The emergence and increasing adoption of online platforms and gig economy models for home services, which connect consumers directly with independent plumbers and local service providers, poses an emerging threat to Chemed's Roto-Rooter segment. These platforms, such as Angi (formerly Angie's List and HomeAdvisor), Thumbtack, and various local equivalents, facilitate price comparison, increase transparency, and offer a wider range of choices for consumers. This model directly challenges Roto-Rooter's traditional brand-driven customer acquisition and service delivery, potentially leading to increased competition, pressure on pricing, and market share erosion, particularly for non-emergency or routine services. This parallels the historical disruption of traditional taxicab businesses by platforms like Uber.

AI Analysis | Feedback

Chemed Corporation (symbol: CHE) operates primarily through two wholly-owned subsidiaries: VITAS Healthcare and Roto-Rooter, both predominantly serving the U.S. market.

VITAS Healthcare

VITAS Healthcare is the largest provider of end-of-life hospice care services in the United States. The addressable market for VITAS Healthcare's services, the U.S. palliative and hospice care industry, was valued at more than $28.6 billion as of June 2020.

Roto-Rooter

Roto-Rooter is recognized as the largest provider of plumbing repair and sewer/drain cleaning services in North America. The broader U.S. Home Service Market, which includes plumbing services, is estimated to reach approximately $0.87 trillion in 2025 and is projected to grow to $1.42 trillion by 2030.

AI Analysis | Feedback

Chemed Corporation (CHE) is expected to drive future revenue growth over the next two to three years through several key initiatives across its two primary segments, VITAS Healthcare and Roto-Rooter.

1. Strategic Acquisitions and Geographic Expansion for VITAS Healthcare: VITAS Healthcare is actively pursuing acquisitions and expanding its geographic footprint. The company made a significant return to the M&A market with the acquisition of Covenant Health in 2024, which has been outperforming expectations and contributing to revenue growth. VITAS is actively seeking new targets in at least 12 states where it currently does not operate, with a particular focus on Certificate of Need (CON) states. Additionally, VITAS is expanding its presence within existing states, such as opening new operations in Marion County, Florida, following CON approval.
2. Organic Growth in VITAS Healthcare through Increased Admissions and Average Daily Census (ADC): VITAS has demonstrated consistent organic growth, marked by sequential quarters of increased average daily census (ADC) and admissions. This growth is being fueled by an increase in clinical capacity, achieved through successful recruitment and retention strategies, including temporary bonus programs and community awareness initiatives. Furthermore, VITAS is focusing on expanding hospital-based admissions as a strategic initiative to navigate Medicare Cap limitations and support sustainable long-term growth. Medicare reimbursement rate increases, such as the 3.2% increase in Q1 2025, a 4.2% increase in Q2 2025, and a 4.1% increase in Q3 2025, also contribute to VITAS's revenue growth.
3. Expansion of Roto-Rooter's Commercial Business and Service Offerings: Roto-Rooter anticipates continued revenue growth from its commercial segment, particularly in excavation and water restoration services. The company reported a significant 7.3% increase in commercial revenue in Q1 2025, driven by a 38% rise in excavation and a 14% increase in water restoration. Roto-Rooter is also refining its pricing models for large commercial excavation projects to optimize revenue growth while balancing EBITDA margins.
4. Roto-Rooter's Enhanced Market Share through Brand Awareness and Operational Efficiency: Management believes Roto-Rooter is well-positioned to expand its market share by leveraging its strong brand awareness, quick customer response times, and 24/7 call centers and internet presence. The company is also implementing e-marketing initiatives to reach younger audiences across various social media platforms, contributing to increased brand visibility and customer acquisition.

AI Analysis | Feedback

Share Repurchases

• Chemed's Board of Directors authorized an additional $300 million for stock repurchase under its existing program on August 1, 2025.
• Another $300 million was authorized for stock repurchase on November 8, 2024.
• In the third quarter of 2025, the company repurchased 407,500 shares for $180.8 million, with approximately $301.8 million of authorization remaining as of September 30, 2025.

Share Issuance

• No significant share issuances (dollar amount) were explicitly detailed in the provided information for the last 3-5 years.

Outbound Investments

• In April 2024, VITAS Healthcare acquired Covenant Health's hospice assets for $85.0 million, contributing to revenue in Q1 2025.
• During 2024, Roto-Rooter acquired three franchises: one in New Jersey for $5.8 million, one in Texas for $1.5 million, and one in Kentucky for $5.1 million, all paid in cash.

Capital Expenditures

• Capital expenditures for the last 12 months (as of current time, November 2025) were reported as -$59.21 million.
• In the first quarter of 2025, Chemed spent $13.3 million on capital expenditures, supporting long-term growth.
• For the full year 2024, capital expenditures amounted to -$50 million. The forecast low consensus for the upcoming fiscal year is $61 million.